Verrica Pharmaceuticals Inc. VRCA

VRCA Company Overview

Verrica Pharmaceuticals Inc. is a U.S.-based dermatology therapeutics company focused on developing and commercializing treatments for medical dermatology conditions that have limited approved therapeutic options. The company operates primarily within the prescription dermatology and specialty pharmaceutical industries, with an emphasis on therapies administered or prescribed by dermatologists and other healthcare professionals. Verrica’s core commercial focus is on treatments for skin diseases caused by viral infections and other dermatologic conditions requiring office-based or physician-supervised care.

The company’s primary revenue driver is YCANTH® (VP-102), a proprietary topical cantharidin-based therapy approved in the United States for the treatment of molluscum contagiosum in adult and pediatric patients aged two years and older. Verrica has also advanced additional investigational programs involving cantharidin-based formulations for other dermatologic indications. The company was founded in 2013 and evolved from a clinical-stage biotechnology company into a commercial-stage specialty pharmaceutical company following the U.S. regulatory approval and launch of YCANTH. Verrica’s strategic positioning centers on proprietary drug-delivery technology, physician-administered dermatology therapies, and the commercialization of products targeting underserved dermatologic conditions.